Skip to main navigation
How Sol-Gel is Responding to Covid-19
LEARN MORE

Main navigation

  • About
    • Who We Are
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Generics
  • Technology
  • Therapeutic Areas
    • Acne Vulgaris
    • Subtype II Papulopustular Rosacea
    • Palmoplantar Keratoderma
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Analyst Coverage
    • Financial Information
      • Proxy Statements
    • Stock Information
    • Shareholder Services
  • Contact

Proxy Statements

Sol-Gel Proxy Statement for AGM May 2018 220.1 KB
Sol-Gel Proxy Statement March 2018 131.1 KB

Investor Relations

  • Investor Overview
  • Press Releases
  • Events & Presentations
    • Events
  • Corporate Governance
    • Documents and Charters
    • Committee Composition
  • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Proxy Statement
  • Stock Information
    • Stock Quote & Chart
  • Shareholder Services
    • FAQs
    • Contact
    • Email Alerts

Shareholder Tools

Print
Print
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds

Who We Are

We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

What We Do

Footer What We Do

  • About
  • Technology
  • Pipeline

Get In Touch

Footer Get In Touch

  • Contact Us
  • Partnering

Subscribe!

Subscribe to receive updates
Sign-up

© 2022 Sol-Gel Technologies Ltd. All Rights Reserved